Feedback / Questions
tosposertib (NCE 401) - Tium Bio, Chiesi
https://www.prnewswire.com/news-releases/tiumbio-to-present-phase-2a-interim-data-highlighting-differentiated-clinical-profile-for-tosposertibtu2218-plus-pembrolizumab-in-first-line-rm-hnscc-at-asco-2026-302786558.html
May 31, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next